Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9078509 | 0.98 | KDM5A (0.49) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| Acetic Acid SCHEMBL30338415 | 0.95 | KDM5A (0.47) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL5393582 | 0.93 | KDM5A (0.58) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| Ammonia Solution, Strong SCHEMBL5785391 | 0.91 | KDM5A (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL9155100 | 0.91 | GPR84 (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL708830 | 0.91 | GPR84 (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL6649565 | 0.91 | KDM5A (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL9148396 | 0.91 | GPR84 (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL11621162 | 0.91 | GPR84 (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG | |
| SCHEMBL9152115 | 0.91 | GPR84 (0.56) | AKR1B1KDM5AKDM4CGPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-117024381-A | Cabazitaxel derivative and liposome preparation thereof | 沈阳药科大学 | 2023-11-10 | — | — | CN | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SUZHOU HEALIRNA BIOTECHNOLOGY CO., LTD. (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4650349-A1 | COMPOUND, PREPARATION METHOD, AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITION THEREOF | Suzhou Healirna Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025090525-A1 | LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO T CELLS | TESSERA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025059607-A9 | LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO CELLS | TESSERA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025059599-A1 | LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO CELLS | TESSERA THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059607-A1 | LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO CELLS | TESSERA THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025005990-A1 | LIPID NANOPARTICLE FORMULATIONS FOR CELL THERAPY AND RELATED METHODS | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-01-02 | — | — | WO | disclosed |
| US-5994364-A | ANTITUMOR, ANTICARCINOGENIC AGENTS | SCHERING CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0929544-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998011092-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5650410-A | ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0749426-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS, IN PARTICULAR FOR TREATING ARTHRITIS | Takeda Chemical Industries, Ltd. (JP) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024394-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS, IN PARTICULAR FOR TREATING ARTHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-09-14 | — | — | WO | disclosed |
| US-4113972-A | ANTIDEPRESSANTS | BEECHAM GROUP LIMITED (GB) | 1978-09-12 | — | — | US | disclosed |
| US-4101676-A | Diphenylpropylamines to treat depression | BEECHAM GROUP LIMITED (GB) | 1978-07-18 | — | — | US | disclosed |
| US-3976633-A | ANORECTIC, ANTIOBESITY | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SGMS1, LDLR, NR5A1 | AKR1B1 345/4885KDM5A 3633/4885KDM4C 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.